CN103476255A - 用于改善认知功能的方法和组合物 - Google Patents

用于改善认知功能的方法和组合物 Download PDF

Info

Publication number
CN103476255A
CN103476255A CN201280014797XA CN201280014797A CN103476255A CN 103476255 A CN103476255 A CN 103476255A CN 201280014797X A CN201280014797X A CN 201280014797XA CN 201280014797 A CN201280014797 A CN 201280014797A CN 103476255 A CN103476255 A CN 103476255A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
solvate
hydrate
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280014797XA
Other languages
English (en)
Chinese (zh)
Inventor
M·加拉格尔
R·哈伯曼
M·T·寇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to CN201811403097.5A priority Critical patent/CN109662961A/zh
Publication of CN103476255A publication Critical patent/CN103476255A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201280014797XA 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物 Pending CN103476255A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811403097.5A CN109662961A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441251P 2011-02-09 2011-02-09
US61/441,251 2011-02-09
PCT/US2012/024556 WO2012109491A1 (en) 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811403097.5A Division CN109662961A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Publications (1)

Publication Number Publication Date
CN103476255A true CN103476255A (zh) 2013-12-25

Family

ID=46638963

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280014797XA Pending CN103476255A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物
CN201811403097.5A Pending CN109662961A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811403097.5A Pending CN109662961A (zh) 2011-02-09 2012-02-09 用于改善认知功能的方法和组合物

Country Status (9)

Country Link
US (2) US20120214859A1 (enExample)
EP (2) EP2672822A4 (enExample)
JP (7) JP2014505108A (enExample)
CN (2) CN103476255A (enExample)
AU (6) AU2012214303A1 (enExample)
BR (1) BR112013020283A2 (enExample)
CA (1) CA2826765C (enExample)
RU (1) RU2665021C2 (enExample)
WO (1) WO2012109491A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063414A1 (zh) * 2019-09-30 2021-04-08 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144546A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
AU2016268096B2 (en) * 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP4499154A1 (en) 2022-03-25 2025-02-05 REGENXBIO Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN115517682B (zh) * 2022-11-25 2023-01-31 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
CN101068534A (zh) * 2005-07-26 2007-11-07 Ucb医药有限公司 包括左乙拉西坦的药物组合物及其制备方法
CN101647789A (zh) * 2009-09-01 2010-02-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂及其制备方法
WO2010044878A1 (en) * 2008-10-16 2010-04-22 The Johns Hopkins University Methods and compositions for improving cognitive function
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1625378A4 (en) * 2002-12-03 2007-05-16 Ucb Sa METHOD OF IDENTIFYING AGENTS FOR THE TREATMENT OF CEREALS, NEUROLOGICAL DISEASES, ENDOCRINOPATHIES AND HORMONE DISEASES
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CN101506157B (zh) * 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US10806717B2 (en) * 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
CN101068534A (zh) * 2005-07-26 2007-11-07 Ucb医药有限公司 包括左乙拉西坦的药物组合物及其制备方法
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
WO2010044878A1 (en) * 2008-10-16 2010-04-22 The Johns Hopkins University Methods and compositions for improving cognitive function
CN101647789A (zh) * 2009-09-01 2010-02-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂及其制备方法
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱杰 等: "阿尔茨海默氏病及其药物治疗研究进展", 《广州化学》, vol. 29, no. 2, 30 June 2004 (2004-06-30) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063414A1 (zh) * 2019-09-30 2021-04-08 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用

Also Published As

Publication number Publication date
CA2826765A1 (en) 2012-08-16
AU2016202670A1 (en) 2016-05-19
JP2014505108A (ja) 2014-02-27
US20230033195A1 (en) 2023-02-02
RU2018129580A3 (enExample) 2022-03-25
EP2672822A4 (en) 2014-08-27
AU2018201303A1 (en) 2018-03-15
WO2012109491A1 (en) 2012-08-16
AU2021200325A1 (en) 2021-03-18
US20120214859A1 (en) 2012-08-23
EP2672822A1 (en) 2013-12-18
JP2023126654A (ja) 2023-09-07
AU2019268069A1 (en) 2019-12-12
RU2018129580A (ru) 2019-03-20
JP2020079318A (ja) 2020-05-28
RU2665021C2 (ru) 2018-08-24
AU2012214303A1 (en) 2013-09-12
JP2018100305A (ja) 2018-06-28
JP2016172772A (ja) 2016-09-29
BR112013020283A2 (pt) 2016-07-19
RU2013141155A (ru) 2015-03-20
JP2025109773A (ja) 2025-07-25
AU2022221492A1 (en) 2022-09-22
CN109662961A (zh) 2019-04-23
AU2021200325B2 (en) 2022-07-28
EP3400934A1 (en) 2018-11-14
CA2826765C (en) 2021-04-06
JP2021175759A (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
US20230277501A1 (en) Methods and compositions for improving cognitive function
US20230033195A1 (en) Methods and compositions for improving cognitive function
US10624875B2 (en) Methods and compositions for treating schizophrenia
CA2789014C (en) Methods and compositions for improving cognitive function
US20160030391A1 (en) Methods and compositions for improving cognitive function
HK40003608A (en) Methods and compositions for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
AU2018208662B2 (en) Methods and Compositions for Treating Schizophrenia
HK1261244A1 (en) Levetiracetam for improving cognitive function
HK40021943A (en) Methods and compositions for treating schizophrenia
HK1192821A (en) Methods and compositions for improving cognitive function
AU2013344646A1 (en) Methods and compositions for treating schizophrenia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192821

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20131225

RJ01 Rejection of invention patent application after publication